FIT Biotech is a clinical-stage biotech company transforming the health care system by developing significantly innovative antibody gene delivery technologies and gene vaccines for cancer immunotherapy as well as the prevention and treatment of infectious diseases such as HIV.
FIT Biotech possesses over 20 years of cutting edge scientific research experience. Our competitive advantage stems from our internally developed and patented GTU® gene delivery technology. It enables development of a multitude of superior drug candidates for different applications. FIT Biotech drug development efforts mainly focus on discovery and development up to phase II clinical testing.
The gene based antibody therapies we are developing are already marketed as protein products. This alternative mode of therapy is expected to be substantially cheaper, safer to dose, more effective, and much better accepted by patients as the antibodies will be produced by the human body. Compliance should improve significantly.
The monoclonal gene based antibodies developed by us are currently available as injectable proteins.
We seek to replace these injected proteins by instead delivering the gene(s) to the patient so they can manufacture their own protein drug.
FIT Biotech plans to license its drug candidates to corporate partners capable for further clinical development, soliciting marketing authorization and commercializing the drugs.
We have multiple in-house drug development projects as well as collaborative projects with other international biotech companies, pharmaceutical companies as well as academic research institutions.